Mortality and recurrence after treatment of VTE: Long term follow-up of patients with good life-expectancy

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 540-546

  Andresen, Marianne S ^a   Sandven, Irene ^b   Brunborg, Cathrine ^b   Njaastad, Anne Mette ^a   Strekerud, Finn ^a   Abdelnoor, Michael ^b   Smith, Pål ^c   Abildgaard, Ulrich ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Mortality; Recurrence; Risk factor; Venous thromboembolism

Indexed keywords

D DIMER;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMOBILIZATION; INCIDENCE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SURVIVAL RATE; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 79957594106     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.02.017     Document Type: Article

References (40)

1. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125(1): 1-7.
2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5(4):692-9. (Pubitemid 46563566)
3. Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151(5):933-8.
4. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362(9383):523-6. (Pubitemid 36976716)
5. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160(6):769-74. (Pubitemid 30165237)
6. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92(2):199-205.
7. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29(3):298-310.
8. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008;149(7):481-90 W94.
9. Bounameaux H, Perrier A. Duration of anticoagulation therapy for venous thromboembolism. Hematology Am Soc Hematol Educ Program 2008;2008:252-8.
10. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 8th Edition, 133(6 Suppl); 2008. p. 454S-545S.
11. Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 8th Edition, 133(6 Suppl); 2008. p. 257S-98S.
12. Eikelboom JW, Ginsberg JS, Hirsh J. Anticoagulation for venous thromboembolism. BMJ 2007;334(7595):645. (Pubitemid 46639823)
13. Odegård OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis 1976;5(5):265-75. (Pubitemid 8032103)
14. Odegaard OR, Try K, Andersson TR. Protein C: an automated activity assay. Haemostasis 1987;17(3):109-13.
15. Wolf M, Boyer-Neumann C, Martinoli JL, Leroy-Matheron C, Amiral J, Meyer D, et al. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989;62(4):1144-5. (Pubitemid 20011505)
16. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997;43(9):1678-83. (Pubitemid 27396369)
17. Schjetlein R, Sletnes KE, Wisløff F. A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thromb Res 1993;69(2):239-50. (Pubitemid 23068248)
18. Kario K, Matsuo T, Kabayashi H, Matsuo M, Yamamoto K, Sakurai G, et al. Rapid quantitative evaluation of plasma D-dimer levels in thrombotic states using an automated latex photometric immunoassay. Thromb Res 1992;66(2-3):179-89.
19. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Breslow NA. Generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns cencorship. Biometrica 1970;57:579-94.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
22. Cox DR. Regression model and life table. JR Stat Soc 1972;B34:187.
23. Andersen PK. Testing goodness of fit of the Cox's regression and life model. Biometrics 1982;38:67-77.
24. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. New York: Van Nostrand Reinhold Company; 1982. p. 320-376.
25. Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 2008;168(4):425-30. (Pubitemid 351347134)
26. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med May 22 1995;155(10):1031-7.
27. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med Mar. 8 1999;159(5):445-53. (Pubitemid 29108909)
28. Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P, et al. Postthrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006;4(4):734-42.
29. Huerta C, Johansson S, Wallander MA, Rodríguez LA. Risk of myocardial infarction and overall mortality in survivors of venous thromboembolism. Thromb J Aug. 18 2008;6:10.
30. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293(19):2352-61. (Pubitemid 40676757)
31. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004;2(12):2152-5. (Pubitemid 40185775)
32. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350(25):2558-63.
33. Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost Nov. 2008;100(5):780-8.
34. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87(1):7-12. (Pubitemid 34092568)
35. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003;290 (8):1071-4. (Pubitemid 37430448)
36. Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost Apr. 1997;77(4):624-8. (Pubitemid 27182953)
37. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med Sep. 9 1999;341(11):801-6. (Pubitemid 29420475)
38. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007;92(8):1107-14. (Pubitemid 350144218)
39. Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger NJ, van der Meer J. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009;101(1):93-9.
40. Weitz JI. Unanswered questions in venous thromboembolism. Thromb Res 2009;123(Suppl 4):S2-S10.